Platelets are small cells but very potent immune cell!!
Research axe
Platelets and inflammation
Platelets are key players in thrombosis and coagulation. Though anucleated, they are also considered as immune cells playing a role in inflammation, which is the main interest of our research group. Hence, we investigate the inflammatory platelet response in biostress situations such as infection but also in transfusion, and aging with ex vivo, in vitro and in vivo approaches.
Transfusion
- Improvement and evaluation of platelet concentrate preparation processes to optimize transfusion yield and promote the development of personalized transfusion.
Infection
- Deciphering the fundamental mechanisms regulating the platelet thrombo-inflammatory response during infection to define new molecular targets and develop strategies to regulate the platelet anti-infectious thrombo-inflammatory response.
Aging
- Inflammatory role of platelets in aging population: investigation of biomarkers of platelet’s stress during ageing to define new targets.
Projects
Assessment of Quality and Inflammatory Profile of Blood Products in Individuals with Type 1 Anti-IFN Autoantibodies
COVIFERON – BEAUTY (Blood componEnt inflAmmation qUaliTY)
Description
Characterization of individuals with autoantibodies against type I IFNs and other cytokines To assess the impact of autoantibodies to type I IFNs or other cytokines on blood products and in transfused recipients. Aims: 1. To evaluate the quality of blood components in donations from donors with autoantibodies. 2. To screen for mediators of inflammation in donations from donors with autoantibodies.
Members
Project Leader : Pr. JM Casanova (IMAGINE Institute)
Researchers involved :
Lab scientists involved:
Student involved :
TBA
ANR-21-RHUS-0008 PIA
Data share among HEAlthcare information SYstems : Application in PLAtelet concentrate Transfusion
HEASY_PLAT
Description
The role of Platelet Concentrate (PCs) in adverse reactions (ARs) and low transfusion yield could be related to the inflammatory function of platelets. While platelets contribute to the haemostatic response, they also function as innate immune cells that can trigger pro-inflammatory events. This study aims to further the understanding of proper and improper use of PCs. This project consists of a follow-up on the characteristics of CPs, recipients, their associated pathology, and parameters related to the effectiveness of platelet transfusion. Various approaches, including in vitro and in vivo studies, will be employed, complemented by data from the EFS and the clinical University Hospital Center of Saint-Etienne database. “Machine learning” methods will be utilized to develop a PC delivery decision tree for personalized transfusion. These optimization algorithms will enable the best matching of patients with available platelet products, thereby reducing the risk of adverse reactions and increasing platelet transfusion yield by considering features of both patients and platelet products. Ultimately, the objectives are to develop an automated blood unit selection model for the personalized matching of transfusions and improve demand prediction models to enhance inventory management practices and minimize wastage.
Members
Project Leader : Dr. Fabrice Cognasse
Researchers involved :
Lab scientists involved:
Student involved :
TBA
Funding
ANR
Université Jean Monnet
Etablissement Francais du Sang
Association les amis de Rémi
Platelet repair system-based biotherapy of amyotrophic lateral sclerosis combining theragnostic biomarkers
SECRET-GIFT
Description
The objective of SECRET-GIFT is to demonstrate the feasibility, safety and initial efficacy data of the HPPL biotherapy with continuous i.c.v. administration in early-stage ALS patients.
Our proactive and committed management team and high-level international scientific council will make strategic decisions to carry-out the project (WP1). We will propose the best combination of classical and new biomarkers with meaningful prognostic and theragnostic value (WP2) to be then used to predict progression and stratify patients (slow progressor versus fast progressor) for our phase Ib/IIb clinical trial on early-stage ALS patients treated with i.c.v. HPPL (WP4). In parallel, InVenis Biotherapies (a start-up, spin off of our research labs at NeuroTMU Lille, supported by the French ALS Association and the ILAB national award) has validated the production of HPPL and its biocompatibility with the i.c.v. device to launch the clinical trial. Etablissement Français du Sang Auvergne-Rhône-Alpes (EFS AuRA) will provide clinical-grade platelet concentrates (PC) collected from healthy donors. All components of the therapy are defined and already validated and will seek regulatory approval during WP3. The safety of HPPL biotherapy, already proven in in vitro and in vivo studies, will further be confirmed in compliance with GLP in healthy monkeys. Biomarkers (WP2) and toxicologic studies (WP3) within two years will allow the start of the clinical trial (WP4) at the end of the second year of the project and for 3 years. The same public-private consortium has already succeeded leading such a clinical trial on brain infusion of A-dopamine in PD (DIVE-1 study). The recruitment of early-stage ALS patients will be done in our expert centre with the support of the French ALS network (ACT4ALS). The placebo controlled randomized clinical trial of 12 months with a delayed start of 6 months is designed to allow a relevant analysis of safety (phase I) and provide a first demonstration of efficacy (phase II) based on classical clinical criteria (functional disability, ALSFRS-R), imaging and biological biomarkers defined in WP2. The findings go through international dissemination (WP5).
We expect to demonstrate i) the safety profile of i.c.v. HPPL administration, ii) the slow-down of the slope of functional handicap (ALS Functional Rating Scale, ALSFRS-r) associated with a combination of theragnostic biomarkers. These new biomarkers will also support other therapeutic developments in neuroprotection. We aim at demonstrating a lower rate of decline by 0.4 of ALSFRS-r under HPPL treatment. Such an effect in the treated population would represent a major advance to facilitate the implementation of large-scale phase II/III trials and later on the registration of this HPPL biotherapy. ALS patients would then benefit from this powerful treatment with truly significant impact on life expectancy and quality of life.
Such a fully innovative HPPL therapeutic concept could be a game changer for NDD.
Members
Project Leader : Pr. David Devos ( U. Lille /UMR-172/Neuro TMU Lille)
Researchers involved :
Lab scientists involved:
Student involved :
TBA
Funding
ANR
Team
Scientific DirectorFabrice Cognasse, PhD
Senior Scientist – Research EngineerHind Hamzeh-Cognasse, PhD
EFS Scientific ResearcherAnne-Claire Duchez, PhD
Laboratory scientistCharles Antoine Arthaud
Laboratory scientistMarie-Ange Eyraud
Laboratory scientistAmélie Prier
Biotechnology Engineer Coop training courseMaïlys Portier
Postdoctoral researcherMarco Heestermans, PhD
PhD studentChloé Heranney
